HIV in pregnancy: Difference between revisions
From IDWiki
(→) |
(→: added orange colour) |
||
Line 73: | Line 73: | ||
|- |
|- |
||
| [[DTG]] |
| [[DTG]] |
||
| style="color: |
| style="color:goldenrod" | Avoid in T1,<br />then preferred |
||
| style="color:darkred" | Avoid in T1 |
| style="color:darkred" | Avoid in T1 |
||
| style="color:darkred" | Avoid in T1 |
| style="color:darkred" | Avoid in T1 |
||
Line 92: | Line 92: | ||
| [[EVG-COBI]] |
| [[EVG-COBI]] |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color: |
| style="color:goldenrod" | Consider switch |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
Line 118: | Line 118: | ||
| [[ATV/COBI]] |
| [[ATV/COBI]] |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color: |
| style="color:goldenrod" | Consider switch |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
Line 124: | Line 124: | ||
| [[DRV/COBI]] |
| [[DRV/COBI]] |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color: |
| style="color:goldenrod" | Consider switch |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
Line 183: | Line 183: | ||
|- |
|- |
||
| [[ABC]]-[[DTG]]-[[3TC]] |
| [[ABC]]-[[DTG]]-[[3TC]] |
||
| style="color: |
| style="color:goldenrod" | Avoid T1 (DTG),<br />then preferred |
||
| style="color: |
| style="color:goldenrod" | Consider switch if T1 |
||
| style="color: |
| style="color:goldenrod" | Avoid T1 (DTG),<br />then preferred |
||
| style="color:darkred" | Not recommended (DTG) |
| style="color:darkred" | Not recommended (DTG) |
||
|- |
|- |
||
Line 226: | Line 226: | ||
| [[EVG/COBI]]-[[FTC]]-[[TDF]] |
| [[EVG/COBI]]-[[FTC]]-[[TDF]] |
||
| style="color:darkred" | Not recommended (EVG/c) |
| style="color:darkred" | Not recommended (EVG/c) |
||
| style="color: |
| style="color:goldenrod" | Consider switch |
||
| style="color:darkred" | Not recommended (EVG/c) |
| style="color:darkred" | Not recommended (EVG/c) |
||
| style="color:darkred" | Not recommended (EVG/c) |
| style="color:darkred" | Not recommended (EVG/c) |
||
Line 232: | Line 232: | ||
| [[EVG/COBI]]-[[FTC]]-[[TAF]] |
| [[EVG/COBI]]-[[FTC]]-[[TAF]] |
||
| style="color:darkred" | Not recommended (EVG/c) |
| style="color:darkred" | Not recommended (EVG/c) |
||
| style="color: |
| style="color:goldenrod" | Consider switch |
||
| style="color:darkred" | Not recommended (EVG/c) |
| style="color:darkred" | Not recommended (EVG/c) |
||
| style="color:darkred" | Not recommended (EVG/c) |
| style="color:darkred" | Not recommended (EVG/c) |
||
Line 238: | Line 238: | ||
| [[DRV/COBI]]-[[FTC]]-[[TAF]] |
| [[DRV/COBI]]-[[FTC]]-[[TAF]] |
||
| style="color:darkred" | Not recommended (DRV/c) |
| style="color:darkred" | Not recommended (DRV/c) |
||
| style="color: |
| style="color:goldenrod" | Consider switch |
||
| style="color:darkred" | Not recommended (DRV/c) |
| style="color:darkred" | Not recommended (DRV/c) |
||
| style="color:darkred" | Not recommended (DRV/c) |
| style="color:darkred" | Not recommended (DRV/c) |
||
Line 244: | Line 244: | ||
| [[DTG]]-[[RPV]] |
| [[DTG]]-[[RPV]] |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color: |
| style="color:goldenrod" | Consider switch |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
||
| style="color:darkred" | Not recommended |
| style="color:darkred" | Not recommended |
Revision as of 19:27, 4 December 2019
Background
- Vertical transmission of HIV occurs in 1/3 of patients if untreated, but less than 1% if treated
- Risk of transmission is proportional to viral load at delivery and goes down with treatment
Epidemiology
- An increasing problem with the increase in effectiveness of antiretroviral therapy
- Decreasing vertical transmission over time
Management
- Monitor viral load monthly during pregnancy
- Routine HIV management including vaccinations (including TDaP)
Initial regimens for treatment-naive women
- NRTI backbones
- INSTI regimens
- PI regimens
Safety in pregnancy
Drug | Starting | Continuing | Restarting | Conceiving |
---|---|---|---|---|
NRTIs | ||||
ABC | Preferred | Continue | Preferred | Preferred |
FTC | Preferred | Continue | Preferred | Preferred |
3TC | Preferred | Continue | Preferred | Preferred |
TDF | Preferred | Continue | Preferred | Preferred |
ZDV | Alternative | Continue | Alternative | Alternative |
TAF | No data | Continue | No data | No data |
Integrase Inhibitors | ||||
DTG | Avoid in T1, then preferred |
Avoid in T1 | Avoid in T1 | Not recommended |
RAL | Preferred | Continue | Preferred | Preferred |
BIC | No data | No data | No data | No data |
EVG-COBI | Not recommended | Consider switch | Not recommended | Not recommended |
Protease Inhibitors | ||||
ATV/r | Preferred | Continue | Preferred | Preferred |
DRV/r | Preferred | Continue | Preferred | Preferred |
LPV/r | Alternative | Continue | Alternative | Alternative |
ATV/COBI | Not recommended | Consider switch | Not recommended | Not recommended |
DRV/COBI | Not recommended | Consider switch | Not recommended | Not recommended |
NNRTIs | ||||
EFV | Alternative | Continue | Alternative | Alternative |
RPV | Alternative | Continue | Alternative | Alternative |
DOR | No data | No data | No data | No data |
ETR | Not recommended | Continue | Not recommended | Not recommended |
NVP | Not recommended | Continue | Not recommended | Not recommended |
Entry Inhibitors & Fusion Inhibitors | ||||
IBA | No data | No data | No data | No data |
MVC | Not recommended | Continue | Not recommended | Not recommended |
T-20 | Not recommended | Continue | Not recommended | Not recommended |
Fixed Drug Combinations | ||||
ABC-DTG-3TC | Avoid T1 (DTG), then preferred |
Consider switch if T1 | Avoid T1 (DTG), then preferred |
Not recommended (DTG) |
EFV-FTC-TDF | Alternative (EFV) | Continue | Alternative (EFV) | Alternative (EFV) |
EFC-3TC-TDF | Alternative (EFV) | Continue | Alternative (EFV) | Alternative (EFV) |
FTC-RPV-TDF | Alternative (RPV) | Continue (RPV) | Alternative (RPV) | Alternative (RPV) |
BIC-FTC-TAF | No data (BIC/TAF) | No data (BIC) | No data (BIC/TAF) | No data (BIC/TAF) |
DOR-3TC-TDF | No data (DOR) | No data (DOR) | No data (DOR) | No data (DOR) |
FTC-RPV-TAF | No data (TAF) | Continue (RPV/TAF) | No data (TAF) | No data (TAF) |
EVG/COBI-FTC-TDF | Not recommended (EVG/c) | Consider switch | Not recommended (EVG/c) | Not recommended (EVG/c) |
EVG/COBI-FTC-TAF | Not recommended (EVG/c) | Consider switch | Not recommended (EVG/c) | Not recommended (EVG/c) |
DRV/COBI-FTC-TAF | Not recommended (DRV/c) | Consider switch | Not recommended (DRV/c) | Not recommended (DRV/c) |
DTG-RPV | Not recommended | Consider switch | Not recommended | Not recommended |
- Starting = ART for Pregnant Women Who Have Never Received ARV Drugs and Who Are Initiating ART for the First Time
- Continuing = Continuing ART for Women Who Become Pregnant on an ART Regimen that has been Well Tolerated and Virologically Suppressive
- Restarting = ART for Pregnant Women Who Have Received ARV Drugs in the Past and Who Are Restarting ART
- Conceiving = ART for Nonpregnant Women Who Are Trying to Conceive